Q-omics provides the consensus-scored FTHL17 profile across patient tissues and cancer cell-line models. FTHL17 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, FTHL17 is differentially expressed in 4, with the highest sampling consensus in UCEC. Additionally, FTHL17 RNA expression shows 9,812 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UVM, UCEC, and TGCT as cancer lineages where FTHL17 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FTHL17 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FTHL17 survival associations across molecular data types. FTHL17 RNA expression shows survival associations in the most cancer types (18), followed by mutation status (2) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FTHL17 RNA expression–survival associations across cancer types. High FTHL17 expression shows unfavorable associations in UVM, COAD, LIHC and HNSC, but favorable associations in LUAD and UCS. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .006). Together, the overview and detailed table identify UVM as the clearest survival context for FTHL17 RNA expression.
This table summarizes FTHL17 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in UCEC for RNA.
This table ranks reproducible tumor–normal expression differences for FTHL17. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FTHL17 shows lower tumor expression in KIRC and higher tumor expression in UCEC, LUAD and LUSC. The UCEC box plot shows higher FTHL17 RNA expression in tumor versus normal tissue (log2 FC = +0.250, t-test p = .014).
This table shows molecular features associated with FTHL17 in patient tissues and cancer cell lines. In patient samples, FTHL17 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, FTHL17 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in BREAST and LARGE_INTESTINE.
